Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.56 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 3/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | PPARA | Q07869 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25249514 | 0.82 | TSHR (0.44) | CYP4F2CYP4A11TSHRKDM4EALDH1A1 | |
| SCHEMBL12660596 | 0.82 | KDM4E (0.48) | CYP4F2CYP4A11TSHRKDM4EALDH1A1 | |
| SCHEMBL5524053 | 0.80 | CYP4F2 (0.65) | CYP4F2CYP4A11TSHRKDM4EALDH1A1 | |
| SCHEMBL6260156 | 0.79 | CYP4F2 (0.62) | CYP4F2CYP4A11TSHRKDM4EALDH1A1 | |
| SCHEMBL31075374 | 0.79 | CYP4F2 (0.44) | CYP4F2CYP4A11TSHRKDM4EALDH1A1 | |
| SCHEMBL17052471 | 0.78 | ALDH1A1 (0.47) | CYP4F2CYP4A11TSHRKDM4EALDH1A1 | |
| SCHEMBL6254544 | 0.78 | CYP4F2 (0.85) | CYP4F2CYP4A11KDM4EALDH1A1LMNA | |
| SCHEMBL6257314 | 0.78 | CYP4F2 (0.85) | CYP4F2CYP4A11KDM4EALDH1A1LMNA | |
| SCHEMBL17746737 | 0.77 | CYP4F2 (0.66) | CYP4F2CYP4A11TSHRKDM4EALDH1A1 | |
| SCHEMBL29283450 | 0.77 | CYP4F2 (0.65) | CYP4F2CYP4A11TSHRKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718696-B2 | Methods of treating diabetes using carnitine conjugates as dual prodrugs | SSV THERAPEUTICS, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-20080188444-A1 | Methods of treating various diseases using carnitine conjugates as dual prodrugs | SSV THERAPEUTICS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188444-A1 | Methods of treating various diseases using carnitine conjugates as dual prodrugs | CPT1B, CRAT, SLC25A20 | CYP4F2 492/4885CYP4A11 290/4885TSHR 1453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.